MHRA authorises Diurnal’s CAH therapy Efmody
2nd July 2021 Uncategorised 0Congenital adrenal hyperplasia (CAH) is a rare condition caused by deficiency of adrenal enzymes
More: MHRA authorises Diurnal’s CAH therapy Efmody
Source: News
Congenital adrenal hyperplasia (CAH) is a rare condition caused by deficiency of adrenal enzymes
More: MHRA authorises Diurnal’s CAH therapy Efmody
Source: News
© 1994 - 2026 B.M. Pharmaceuticals